新橋生物 NBP 深 滬
等待開盤 01-28 09:30:00 美东时间
3.98
+0.010
+0.25%
華盛通- 最 高4.075
- 今 開3.98
- 成交量 50.78万股
- 最 低 3.95
- 昨 收 3.97
- 總市值 0
- 52周最高 6.79
- 市盈率 靜 --
- 換手率 Infinity.00%
- 52周最低 0.595
- 委 比 92.60%
- 總股本 --
- 歷史最高 85.40
- 量 比 0.61
- 振 幅 3.15%
- 歷史最低 0.595
- 每 手 1
- 風險率 1.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多“聚能创新 共话湾区”2026生物医药上市公司春季路演 解码创新药投资新逻辑
2026年1月22日-23日，由乐赢投资、国投证券国际、投研会联合主办，智信财经、东莞市私募基金业协会、建国路128号联袂承办，以“聚能创新 共话湾区”为主题举...
01-26 16:22
胃癌一线数据超预期，新桥生物重磅BD呼之欲出
（来源：求实药社） 近日，新桥生物发布公告称，公司执行董事长傅唯自1月15日起，拟在公开市场交易中增持公司至多500万美元的ADS股票。 对于上市公司而言，重要...
01-26 11:56
NovaBridge Executive Chairman Fu Wei Plans Open-Market Purchase of Up to $5M in Stock After Positive Trial Data
NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the
01-20 20:13
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
NovaBridge Biosciences的执行主席Fu Wei计划在公开市场购买最多500万美元的公司ADS，购买始于1月15日。Fu Wei对公司的未来充满信心，提到2025年是NovaBridge的关键一年，包括执行新战略、建立全球平台和积极的1b期数据。NovaBridge致力于加速创新药物的获取，其主要产品包括治疗胃癌的givastomig和用于湿性AMD的VIS-101。
01-20 12:00
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment towa...
01-16 21:00
What's Going On With NovaBridge Stock Tuesday?
NovaBridge stock was trading higher Tuesday but has since reversed and begun trading lower. NovaBridge announced upgrade results from the Phase 1b combination study of givastomig.
01-07 01:14
NovaBridge Highlights Phase 1b Givastomig Combination Results With Strong Responses And Manageable Safety In First-Line Gastric Cancer
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR
01-06 20:04
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
NovaBridge Biosciences, a global biotech platform, announced its inclusion in the Nasdaq Biotech Index (NBI) and that Fu Wei, Executive Chairman, and Sean Fu, CEO, will ring the Nasdaq Opening Bell on January 2, 2026. This highlights NovaBridge's leadership and visibility. The Company's pipeline includes promising assets like givastomig and VIS-101, targeting cancer and eye conditions. For more info, visit www.novabridge.com.
2025-12-30 12:00
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Ragistomig, a bispecific antibody targeting 4-1BB and PD-L1, has shown promising anti-tumor efficacy and improved safety in a Phase 1 study for patients with advanced solid tumors resistant to checkpoint inhibitors. The extended Q6W dosing schedule demonstrated comparable efficacy to the Q2W regimen with fewer side effects. Positive immunological responses, including CD8+ T cell activation, support its potential in combination therapies. NovaBrid...
2025-12-10 21:30
